GSK Shares Rise on Strong Q2 Earnings, Reaffirmed 2026 Guidance

Shares of GSK (GSK) surged in pre-market trading after the British pharmaceutical company announced second-quarter 2026 financial results that beat market expectations and reaffirmed its full-year guidance.

Second-Quarter Performance Exceeds Forecasts

GSK reported total sales of £8.4 billion for the second quarter, a 5% increase year-over-year on a constant exchange rate basis. This figure notably surpassed the analyst consensus estimate of $8.25 billion. The company's core earnings per share rose by 9% to 50.5p, while core operating profit increased by 7% to £2.8 billion.

The robust top-line growth was fueled by strong performance in two key segments:

• Specialty Medicines: Sales grew 14% to £3.8 billion.
• Vaccines: Sales increased by 8% to £2.3 billion.

Strategic Outlook and Reaffirmed Guidance

Ad

Coinciding with the earnings release, GSK hosted an investor event where CEO Luke Miels outlined a long-term strategy to exceed £40 billion in annual sales by 2031. The company also provided updates on its drug pipeline following its acquisition of Nuvalent.

For the full year 2026, GSK reaffirmed its guidance for turnover growth of 3–5% and core operating profit growth of 7–9%, both at constant exchange rates. This confirmation provided investors with additional confidence in the company's operational momentum.

Market Reaction

The stock jumped 3.3% in pre-open trading on the news. The rally was distinctly company-specific, occurring against a backdrop of a mixed and cautious broader market. The positive results were particularly impactful as some analysts had maintained a cautious outlook on the company ahead of the report, citing strategic shifts in its oncology investments.